Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
- PMID: 16011870
- DOI: 10.1016/j.pneurobio.2005.04.006
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
Abstract
The blood-brain barrier (BBB) serves as a protective mechanism for the brain by preventing entry of potentially harmful substances from free access to the central nervous system (CNS). Tight junctions present between the brain microvessel endothelial cells form a diffusion barrier, which selectively excludes most blood-borne substances from entering the brain. Astrocytic end-feet tightly ensheath the vessel wall and appear to be critical for the induction and maintenance of the barrier properties of the brain capillary endothelial cells. Because of these properties, the BBB only allows entry of lipophilic compounds with low molecular weights by passive diffusion. However, many lipophilic drugs show negligible brain uptake. They are substrates for drug efflux transporters such as P-glycoprotein (Pgp), multidrug resistance proteins (MRPs) or organic anion transporting polypeptides (OATPs) that are expressed at brain capillary endothelial cells and/or astrocytic end-feet and are key elements of the molecular machinery that confers the special permeability properties to the BBB. The combined action of these carrier systems results in rapid efflux of xenobiotics from the CNS. The objective of this review is to summarize transporter characteristics (cellular localization, specificity, regulation, and potential inhibition) for drug efflux transport systems identified in the BBB and blood-cerebrospinal fluid (CSF) barrier. A variety of experimental approaches available to ascertain or predict the impact of efflux transport on brain access of therapeutic drugs also are described and critically discussed. The potential impact of efflux transport on the pharmacodynamics of agents acting in the CNS is illustrated. Furthermore, the current knowledge about drug efflux transporters as a major determinant of multidrug resistance of brain diseases such as epilepsy is reviewed. Finally, we summarize strategies for modulating or by-passing drug efflux transporters at the BBB as novel therapeutic approaches to drug-resistant brain diseases.
Similar articles
-
The blood-brain barrier: an overview: structure, regulation, and clinical implications.Neurobiol Dis. 2004 Jun;16(1):1-13. doi: 10.1016/j.nbd.2003.12.016. Neurobiol Dis. 2004. PMID: 15207256 Review.
-
Progress in brain penetration evaluation in drug discovery and development.J Pharmacol Exp Ther. 2008 May;325(2):349-56. doi: 10.1124/jpet.107.130294. Epub 2008 Jan 18. J Pharmacol Exp Ther. 2008. PMID: 18203948 Review.
-
Macromolecular drug transport into the brain using targeted therapy.J Neurochem. 2010 Apr;113(1):1-13. doi: 10.1111/j.1471-4159.2009.06544.x. Epub 2009 Dec 14. J Neurochem. 2010. PMID: 20015155 Review.
-
Structure and function of the blood-brain barrier.Neurobiol Dis. 2010 Jan;37(1):13-25. doi: 10.1016/j.nbd.2009.07.030. Epub 2009 Aug 5. Neurobiol Dis. 2010. PMID: 19664713 Review.
-
Transporter-mediated uptake into cellular compartments.Xenobiotica. 2007 Oct-Nov;37(10-11):1171-95. doi: 10.1080/00498250701570251. Xenobiotica. 2007. PMID: 17968742 Review.
Cited by
-
P-glycoprotein function at the blood-brain barrier: effects of age and gender.Mol Imaging Biol. 2012 Dec;14(6):771-6. doi: 10.1007/s11307-012-0556-0. Mol Imaging Biol. 2012. PMID: 22476967 Free PMC article. Clinical Trial.
-
Fatty Acid Binding Proteins Expressed at the Human Blood-Brain Barrier Bind Drugs in an Isoform-Specific Manner.Pharm Res. 2015 Oct;32(10):3432-46. doi: 10.1007/s11095-015-1764-5. Epub 2015 Aug 7. Pharm Res. 2015. PMID: 26248795
-
Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography.Eur J Pharmacol. 2012 Dec 5;696(1-3):18-27. doi: 10.1016/j.ejphar.2012.09.013. Epub 2012 Sep 26. Eur J Pharmacol. 2012. PMID: 23022332 Free PMC article.
-
Interaction of a Homologous Series of Amphiphiles with P-glycoprotein in a Membrane Environment-Contributions of Polar and Non-Polar Interactions.Pharmaceutics. 2023 Jan 3;15(1):174. doi: 10.3390/pharmaceutics15010174. Pharmaceutics. 2023. PMID: 36678803 Free PMC article.
-
Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats.J Pharm Sci. 2007 Sep;96(9):2494-506. doi: 10.1002/jps.20893. J Pharm Sci. 2007. PMID: 17593551 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous